Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Gets OK for Nasdaq Switch

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CombiMatrix today said that the Nasdaq Stock Market has approved the firm's switch to the Nasdaq Capital Market from the Nasdaq Global Market.

The Irvine, Calif.-based molecular diagnostics firm announced last week that it was voluntarily applying for the transfer rather than submitting a plan to the exchange to regain compliance with Nasdaq Global Market listing requirements. The switch will enable the firm to meet the exchange's listing requirement for shareholders' equity.

The transfer will be effective Friday, and CombiMatrix's shares will continue to trade under the symbol "CBMX."

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.